Abstract: The present invention relates to a method to catalyze the oxidation of Hg(0) in a flue gas stream prior to standard emissions control equipment. The oxidized mercury has been found to be more condensable than Hg(0) and consequently more easily removed from the gas phase. Accordingly, mercury in its oxidized form can be trapped from a flue gas stream or the like by absorption onto a solid mass or can be more efficiently removed from flue gas streams by wet processes such as a two-stage wet FGD. The gist underlying the inventive concept of the instant invention relates to the use of a porous bed of gold-coated material that is saturated with Hg(0) to the point that the gold in the presence of HCl in the exhaust stream catalyses the oxidation of Hg(0).

Abstract: The present invention relates to a system, apparatus, and process to reduce the oxidized mercury in an exhaust gas to elemental mercury and to prevent its reoxidation by congeneric components in the exhaust gas prior to the photometric measurement of said elemental mercury. In the process, the sample stream flows through a reactor heated to preferably about 800.degree. C. in which a stream of hydrogen is introduced directly into a hot portion thereof. The congeneric oxidized mercury species, i.e, HgCl.sub.2, and HgO are thermally reduced quantitatively to elemental mercury. The hydrogen reacts in situ with oxygen to form water vapor and with chlorine to form hydrochloride gas. The hydrochloride gas is effectively absorbed by the water vapor and consequently prevents the reoxidation of elemental mercury. The concentration of total mercury in a stream can then be determined by the intensity of radiation absorbed by a UV spectrometer.

Abstract: The present invention relates to methods and means including a process and system for producing an elemental-mercury-free reference flue gas which is used to obtain background photometric measurements thereby eliminating the photometric interferences of flue gas components to the photometric measurement of mercury. In the process, elemental mercury is selectively removed from a portion of a gaseous stream (the reference portion) and the intensity of radiation absorbed is measured by a UV spectrometer on the resulting mercury-free reference gas, and thereafter the concentration of mercury in the remainder of the gaseous stream is determined through utilization of the ratio of the transmitted radiation of the mercury-containing flue gas with respect to that of the mercury-free reference portion of the gaseous stream. The mercury concentration can then be determined without interference by other absorbing moieties at 254 nm in the flue gas.

Abstract: In binary treatment with cis-dichlorodiamine-platinum(II) (or cisplatin) the preferred ratio of the present compound to cisplatin is about 10:1 with a range of about 10:1 to 1:10 in mg/kg of body weight.As to the variations in the formula on the left hand side of the formula, it may be varied as monodentate, such as cisplatin containing a single amine group proceeding from the ring, or bidentate, such as the present compound. The saturated cyclo ring may be C.sub.4 or C.sub.5 -C.sub.7 in addition to the present cyclohexane.The present platinum compound may be prepared by reacting the known L-aspartic acid, N-(phosphonacetyl-)disodium salt (PALA; NSC-224131), with dinitrato(1,2-diaminocyclohexane)platinum(II) (NSC-239851). This compound N-phosphonacetyl-L-asparato (1,2-diaminocyclohexane)platinum(II) may be combined in multiple drug regimen with substantially improved yield cures over the parent compounds.

Abstract: In binary treatment with cis-dichlorodiamine-platinum(II) (or cisplatin) the preferred ratio of the present compound to cisplatin is about 10:1 with a range of about 10:1 to 1:10 in mg/kg of body weight.As to the variations in the formula on the left hand side of the formula, it may be varied as monodentate, such as cisplatin containing a single amine group proceeding from the ring, or bidentate, such as the present compound. The saturated cyclo ring may be C.sub.4 or C.sub.5 -C.sub.7 in addition to the present cyclohexane.The present platinum compound may be prepared by reacting the known L-aspartic acid, N-(phosphonacetyl-) disodium salt (PALA; NSC-224131), with dinitrato(1,2-diaminocyclohexane)platinum(II) (NSC-239851). This compound N-phosphonacetyl-L-aspartato(1,2-diaminocyclohexane)platinum(II) may be combined in multiple drug regimen with substantially improved yield cures over the parent compounds.

Abstract: Organoplatinum complexes having antineoplastic activity against the L1210 mouse leukemia test system and having sufficient water-solubility for use in aqueous i.v. fluids. The organoplatinum complexes include malonato (1,2-diaminocyclohexane) platinum (II), hydroxymalonato (1,2-diaminocyclohexane) platinum (II), dinitrato (1,2-diaminocyclohexane) platinum (II), sulfato (1,2-diaminocyclohexane) platinum (II), and hydroxonitrato (1,2-diaminocyclohexane) platinum (II).